DK141622B - Analogifremgangsmåde til fremstilling af racemiske eller optisk aktive 1-(3,5-dihydroxyfenyl)-2-aminoætanolderivater eller syreadditionssalte deraf. - Google Patents
Analogifremgangsmåde til fremstilling af racemiske eller optisk aktive 1-(3,5-dihydroxyfenyl)-2-aminoætanolderivater eller syreadditionssalte deraf. Download PDFInfo
- Publication number
- DK141622B DK141622B DK439776AA DK439776A DK141622B DK 141622 B DK141622 B DK 141622B DK 439776A A DK439776A A DK 439776AA DK 439776 A DK439776 A DK 439776A DK 141622 B DK141622 B DK 141622B
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- group
- general formula
- carbon atoms
- dihydroxyphenyl
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims description 9
- 239000002253 acid Substances 0.000 title claims description 6
- VZVBXISLBQEWKU-UHFFFAOYSA-N 5-(2-amino-1-hydroxyethyl)benzene-1,3-diol Chemical class NCC(O)C1=CC(O)=CC(O)=C1 VZVBXISLBQEWKU-UHFFFAOYSA-N 0.000 title claims description 3
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 99
- -1 phenylacetyl group Chemical group 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 31
- 238000002360 preparation method Methods 0.000 claims description 24
- 230000008569 process Effects 0.000 claims description 20
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 66
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 60
- 229960001340 histamine Drugs 0.000 description 33
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 32
- 229960000195 terbutaline Drugs 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 23
- 239000000243 solution Substances 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 238000012360 testing method Methods 0.000 description 20
- 210000004072 lung Anatomy 0.000 description 19
- 241000700199 Cavia porcellus Species 0.000 description 16
- 206010020751 Hypersensitivity Diseases 0.000 description 15
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 14
- 230000000572 bronchospasmolytic effect Effects 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- 229960001317 isoprenaline Drugs 0.000 description 14
- 230000002804 anti-anaphylactic effect Effects 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 11
- 230000007815 allergy Effects 0.000 description 11
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 208000006673 asthma Diseases 0.000 description 9
- 208000026935 allergic disease Diseases 0.000 description 8
- 208000003455 anaphylaxis Diseases 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 230000004936 stimulating effect Effects 0.000 description 8
- VUDSOUNZIXESSU-UHFFFAOYSA-N 5-[1-hydroxy-2-[(1-hydroxy-2-methylpropan-2-yl)amino]ethyl]benzene-1,3-diol;sulfuric acid Chemical compound OS(O)(=O)=O.OCC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1.OCC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 VUDSOUNZIXESSU-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 108010058846 Ovalbumin Proteins 0.000 description 7
- 230000000747 cardiac effect Effects 0.000 description 7
- 229940092253 ovalbumin Drugs 0.000 description 7
- 210000003437 trachea Anatomy 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 206010002198 Anaphylactic reaction Diseases 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 230000003266 anti-allergic effect Effects 0.000 description 5
- 230000008602 contraction Effects 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 229960003712 propranolol Drugs 0.000 description 5
- 229920002307 Dextran Polymers 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000000150 Sympathomimetic Substances 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 4
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 210000003405 ileum Anatomy 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- AADZKTBRIXGHMB-UHFFFAOYSA-N 5-[1-hydroxy-2-[(1-hydroxy-2-methylpropan-2-yl)amino]ethyl]benzene-1,3-diol Chemical compound OCC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 AADZKTBRIXGHMB-UHFFFAOYSA-N 0.000 description 3
- UCTWMZQNUQWSLP-UHFFFAOYSA-N Adrenaline Natural products CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 230000002052 anaphylactic effect Effects 0.000 description 3
- 210000000621 bronchi Anatomy 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- 206010002216 Anaphylactoid reaction Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OCKZRGVNMXEULR-UHFFFAOYSA-N Br.CC(C(=O)OC=1C=C(C=C(C1)OC(C(C)C)=O)C(CNC(CO)(C)C)O)C Chemical compound Br.CC(C(=O)OC=1C=C(C=C(C1)OC(C(C)C)=O)C(CNC(CO)(C)C)O)C OCKZRGVNMXEULR-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KIWBPDUYBMNFTB-UHFFFAOYSA-N Ethyl hydrogen sulfate Chemical compound CCOS(O)(=O)=O KIWBPDUYBMNFTB-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- NSPVKWPCCHFAKJ-UHFFFAOYSA-N [1-[3,5-bis(phenylmethoxy)phenyl]-2-[(1-hydroxy-2-methylpropan-2-yl)amino]ethyl] hydrogen sulfate Chemical compound S(=O)(=O)(O)OC(CNC(CO)(C)C)C1=CC(=CC(=C1)OCC1=CC=CC=C1)OCC1=CC=CC=C1 NSPVKWPCCHFAKJ-UHFFFAOYSA-N 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 210000002159 anterior chamber Anatomy 0.000 description 2
- 150000007514 bases Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000000496 cardiotonic agent Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000003843 mucus production Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 230000003033 spasmogenic effect Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- IXYYQIMVOHFSDN-UHFFFAOYSA-N 2-[3,5-bis(phenylmethoxy)phenyl]oxirane Chemical compound C=1C=CC=CC=1COC(C=C(C=1)C2OC2)=CC=1OCC1=CC=CC=C1 IXYYQIMVOHFSDN-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
- WQXWIKCZNIGMAP-UHFFFAOYSA-N 3',5'-Dihydroxyacetophenone Chemical compound CC(=O)C1=CC(O)=CC(O)=C1 WQXWIKCZNIGMAP-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- ITXGNSLWCVPHKI-UHFFFAOYSA-N 5-[1-hydroxy-2-(2-hydroxypropylamino)ethyl]benzene-1,3-diol hydrochloride Chemical compound Cl.OC=1C=C(C=C(C1)O)C(CNCC(C)O)O ITXGNSLWCVPHKI-UHFFFAOYSA-N 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 229910014033 C-OH Inorganic materials 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 229910014570 C—OH Inorganic materials 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000509579 Draco Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 101150096622 Smr2 gene Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010062119 Sympathomimetic effect Diseases 0.000 description 1
- 101150046432 Tril gene Proteins 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- XFFSMTIQKBYPFE-UHFFFAOYSA-N [1-(3,5-dihydroxyphenyl)-2-[(1-hydroxy-2-methylpropan-2-yl)amino]ethyl] hydrogen sulfate Chemical compound S(=O)(=O)(O)OC(CNC(CO)(C)C)C1=CC(=CC(=C1)O)O XFFSMTIQKBYPFE-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- DPEATBWCWKCPRX-UHFFFAOYSA-N benzyl 2-amino-2-methylpropanoate Chemical compound CC(C)(N)C(=O)OCC1=CC=CC=C1 DPEATBWCWKCPRX-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003506 spasmogen Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/04—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reaction of ammonia or amines with olefin oxides or halohydrins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
- C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE7510988A SE7510988L (sv) | 1975-10-01 | 1975-10-01 | Nya farmaceutiskt aktiva foreningar |
| SE7510988 | 1975-10-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK439776A DK439776A (OSRAM) | 1977-04-02 |
| DK141622B true DK141622B (da) | 1980-05-12 |
Family
ID=20325688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK439776AA DK141622B (da) | 1975-10-01 | 1976-09-30 | Analogifremgangsmåde til fremstilling af racemiske eller optisk aktive 1-(3,5-dihydroxyfenyl)-2-aminoætanolderivater eller syreadditionssalte deraf. |
Country Status (19)
| Country | Link |
|---|---|
| JP (1) | JPS5242840A (OSRAM) |
| AT (1) | AT347427B (OSRAM) |
| AU (1) | AU503212B2 (OSRAM) |
| BE (1) | BE846837A (OSRAM) |
| CS (2) | CS199643B2 (OSRAM) |
| DD (1) | DD126278A5 (OSRAM) |
| DE (1) | DE2640972A1 (OSRAM) |
| DK (1) | DK141622B (OSRAM) |
| ES (1) | ES451979A1 (OSRAM) |
| FI (1) | FI762660A7 (OSRAM) |
| FR (1) | FR2326183A1 (OSRAM) |
| GB (1) | GB1542317A (OSRAM) |
| LU (1) | LU75916A1 (OSRAM) |
| NL (1) | NL7610845A (OSRAM) |
| NO (1) | NO763345L (OSRAM) |
| NZ (1) | NZ182165A (OSRAM) |
| SE (1) | SE7510988L (OSRAM) |
| SU (2) | SU638252A3 (OSRAM) |
| ZA (1) | ZA765331B (OSRAM) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4419364A (en) | 1980-07-09 | 1983-12-06 | Aktiebolaget Draco | Bronchospasmolytic carbamate derivatives |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0103830A3 (de) * | 1982-09-22 | 1985-07-31 | Bayer Ag | Wachstumsfördernde Phenylethylamin-Derivate |
| IL121625A (en) * | 1995-12-28 | 2001-09-13 | Welfide Corp | Preparation containing 2 - amino - 2 - (-2 (-4-octylphenyl) ethyl) propane - 1, 3, - dial for local topical use |
| EP2332921B1 (en) | 2003-06-17 | 2016-03-02 | Arena Pharmaceuticals, Inc. | 8-Chloro-1 -methyl-2,3,4,5-tetrahydro-1 H-3benzazapine Hydrochloride |
| CN101466684B (zh) | 2006-04-03 | 2012-06-20 | 艾尼纳制药公司 | 8-氯-1-甲基-2,3,4,5-四氢-1h-3-苯并氮杂卓的制备工艺和其相关中间体 |
| CA2670285A1 (en) | 2006-12-05 | 2008-06-12 | Arena Pharmaceuticals, Inc. | Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates thereof |
| RU2361604C1 (ru) * | 2007-10-29 | 2009-07-20 | Федеральное агентство по высокотехнологичной медицинской помощи Федеральное государственное учреждение "Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии" (ФГУ УрНИИДВиИ Росмедтехнологий) | Способ лечения атопического дерматита |
| EP2288585A1 (en) | 2008-03-04 | 2011-03-02 | Arena Pharmaceuticals, Inc. | Processes for the preparation of intermediates related to the 5-ht2c agonist (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine |
| EP2443080A2 (en) | 2009-06-18 | 2012-04-25 | Arena Pharmaceuticals, Inc. | Process for the preparation of 5-ht2c receptor agonists |
| US9045431B2 (en) | 2010-06-02 | 2015-06-02 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-HT2C receptor agonists |
| WO2012030939A1 (en) | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | Administration of lorcaserin to individuals with renal impairment |
| KR20130138770A (ko) | 2010-09-01 | 2013-12-19 | 아레나 파마슈티칼스, 인크. | 광학적으로 활성 산을 갖는 로르카세린의 염 |
| EP2611433A2 (en) | 2010-09-01 | 2013-07-10 | Arena Pharmaceuticals, Inc. | Non-hygroscopic salts of 5-ht2c agonists |
| EP3485878A1 (en) | 2010-09-01 | 2019-05-22 | Arena Pharmaceuticals, Inc. | Modified-release dosage forms of 5-ht2c agonists useful for weight management |
| JP2015534563A (ja) | 2012-10-09 | 2015-12-03 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 体重管理の方法 |
-
1975
- 1975-10-01 SE SE7510988A patent/SE7510988L/xx unknown
-
1976
- 1976-09-07 ZA ZA765331A patent/ZA765331B/xx unknown
- 1976-09-11 DE DE19762640972 patent/DE2640972A1/de not_active Withdrawn
- 1976-09-15 AT AT682376A patent/AT347427B/de not_active IP Right Cessation
- 1976-09-16 FI FI762660A patent/FI762660A7/fi not_active Application Discontinuation
- 1976-09-22 SU SU762402852A patent/SU638252A3/ru active
- 1976-09-27 NZ NZ182165A patent/NZ182165A/xx unknown
- 1976-09-27 AU AU18122/76A patent/AU503212B2/en not_active Expired
- 1976-09-28 DD DD195022A patent/DD126278A5/xx unknown
- 1976-09-30 DK DK439776AA patent/DK141622B/da unknown
- 1976-09-30 NO NO763345A patent/NO763345L/no unknown
- 1976-09-30 LU LU75916A patent/LU75916A1/xx unknown
- 1976-09-30 FR FR7629467A patent/FR2326183A1/fr not_active Withdrawn
- 1976-09-30 GB GB7640684A patent/GB1542317A/en not_active Expired
- 1976-09-30 NL NL7610845A patent/NL7610845A/xx not_active Application Discontinuation
- 1976-09-30 ES ES451979A patent/ES451979A1/es not_active Expired
- 1976-10-01 JP JP51118924A patent/JPS5242840A/ja active Pending
- 1976-10-01 BE BE171148A patent/BE846837A/xx unknown
- 1976-10-01 CS CS766357A patent/CS199643B2/cs unknown
- 1976-10-01 CS CS782253A patent/CS199644B2/cs unknown
-
1977
- 1977-10-13 SU SU772532454A patent/SU674669A3/ru active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4419364A (en) | 1980-07-09 | 1983-12-06 | Aktiebolaget Draco | Bronchospasmolytic carbamate derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| NL7610845A (nl) | 1977-04-05 |
| ATA682376A (de) | 1978-05-15 |
| LU75916A1 (OSRAM) | 1978-05-16 |
| AU503212B2 (en) | 1979-08-30 |
| BE846837A (fr) | 1977-04-01 |
| SU638252A3 (ru) | 1978-12-15 |
| GB1542317A (en) | 1979-03-14 |
| DD126278A5 (OSRAM) | 1977-07-06 |
| NZ182165A (en) | 1978-07-10 |
| FR2326183A1 (fr) | 1977-04-29 |
| DK439776A (OSRAM) | 1977-04-02 |
| AT347427B (de) | 1978-12-27 |
| JPS5242840A (en) | 1977-04-04 |
| AU1812276A (en) | 1978-04-06 |
| DE2640972A1 (de) | 1977-04-14 |
| FI762660A7 (OSRAM) | 1977-04-02 |
| ZA765331B (en) | 1977-08-31 |
| CS199644B2 (en) | 1980-07-31 |
| CS199643B2 (en) | 1980-07-31 |
| NO763345L (OSRAM) | 1977-04-04 |
| ES451979A1 (es) | 1978-01-01 |
| SU674669A3 (ru) | 1979-07-15 |
| SE7510988L (sv) | 1977-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK141622B (da) | Analogifremgangsmåde til fremstilling af racemiske eller optisk aktive 1-(3,5-dihydroxyfenyl)-2-aminoætanolderivater eller syreadditionssalte deraf. | |
| DK157678B (da) | Analogifremgangsmaade til fremstilling af amider af hydroxyfenylalkylaminoaetanoler eller terapeutisk acceptable salte deraf samt acetofenonderivat til anvendelse som udgangsmateriale ved fremgangsmaaden | |
| JP6076737B2 (ja) | 高血圧症の防止及び治療のための組成物並びに方法 | |
| US11129807B2 (en) | Methods of treating schizophrenia | |
| Hikino et al. | Antiinflammatory principle of Ephedra herbs | |
| DE2106209B2 (de) | p-substituierte Phenoxypropanolamine, Verfahren zu deren Herstellung und Arzneimittel auf deren Basis | |
| CS266593B2 (en) | Method of 2-(2-hydroxy-3-phenosypropylamine) ethoxyphenolh's derivativesprodduction | |
| AU7326396A (en) | Hydroxylamine derivatives useful for enhancing the molecular chaperon production and the preparation thereof | |
| DD283374A5 (de) | Verfahren zur herstellung von 2-hydroxy-3-phenoxypropylaminoverbindungen | |
| NO174044B (no) | Analogifremgangsmaate for fremstilling av et terapeutisk aktivt amid-derivat | |
| CS208663B2 (en) | Method of making the new r,s-n-/2-phenyl-2-hydroxyethyl0 -1-alkyl-3-/4-substituted phenyl/propylamines | |
| JPS58154538A (ja) | アルキルアミノアルコ−ル誘導体、その製造法、並びに該誘導体を有効成分とする新規薬剤 | |
| JPH06508375A (ja) | インダン−１，３−ジオンおよびインダン−１，２，３−トリオンの誘導体、それらの調製方法およびそれらの治療上の使用 | |
| US3448196A (en) | Method and composition for inducing local anesthesia with mono-(beta-diethylaminoethyl)amide of parachlorophenoxyacetic acid | |
| US2185220A (en) | Medicinal agent | |
| US2460182A (en) | Basic esters of aliphatic tertiary carboxylic acids | |
| US5804603A (en) | Synthesized β-adrenergic blockers derivatives of guaiacol | |
| US3331845A (en) | 1-substituted-4-substituted amino alkylene piperazines | |
| JPS5940179B2 (ja) | 酸化防止剤 | |
| DK151797B (da) | Analogifremgangsmaade til fremstilling af terbutalinderivater eller terapeutisk acceptable salte deraf | |
| DE2651750C2 (OSRAM) | ||
| US3474095A (en) | Beta - morpholinoethyl - alpha - phenoxy-isobutyrate hydrochloride or citrate salt | |
| AT350526B (de) | Verfahren zur herstellung von neuen 2-amino-1- phenylaethanolen -(1) und von deren salzen | |
| EP0073345A2 (en) | Sydnonimine derivatives, process for production thereof, and use thereof | |
| US3549704A (en) | Salicylamides |